{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:02Z","timestamp":1740106922655,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170180","81770126","82000218"],"award-info":[{"award-number":["82170180","81770126","82000218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00277-022-04876-x","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T03:31:47Z","timestamp":1654918307000},"page":"1741-1753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis"],"prefix":"10.1007","volume":"101","author":[{"given":"Weihang","family":"Shan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guixiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanyan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"key":"4876_CR1","doi-asserted-by":"publisher","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 5:1749\u20131768.https:\/\/doi.org\/10.1001\/jamaoncol.2019.2996","DOI":"10.1001\/jamaoncol.2019.2996"},{"key":"4876_CR2","unstructured":"(2015) Non-Hodgkin lymphoma statistics. In: Cancer Research UK. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/non-hodgkin-lymphoma. Accessed 28 Sep 2021"},{"key":"4876_CR3","unstructured":"SEER Cancer Stat Facts. In: SEER. https:\/\/seer.cancer.gov\/statfacts\/index.html. Accessed 28 Sep 2021"},{"key":"4876_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489\u2013501. https:\/\/doi.org\/10.1038\/nrc839","journal-title":"Nat Rev Cancer"},{"key":"4876_CR5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606\u2013619. https:\/\/doi.org\/10.1038\/nrg1879","journal-title":"Nat Rev Genet"},{"key":"4876_CR6","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms22073464","volume":"22","author":"R Mishra","year":"2021","unstructured":"Mishra R, Patel H, Alanazi S et al (2021) PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci 22:3464. https:\/\/doi.org\/10.3390\/ijms22073464","journal-title":"Int J Mol Sci"},{"key":"4876_CR7","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","journal-title":"Cochrane Database Syst Rev"},{"key":"4876_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14740338.2020.1718103","volume":"19","author":"S Gao","year":"2020","unstructured":"Gao S, Zhang M, Wu K et al (2020) Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis. Expert Opin Drug Saf 19:617\u2013623. https:\/\/doi.org\/10.1080\/14740338.2020.1718103","journal-title":"Expert Opin Drug Saf"},{"key":"4876_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","volume":"18","author":"AD Zelenetz","year":"2017","unstructured":"Zelenetz AD, Barrientos JC, Brown JR et al (2017) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 18:297\u2013311. https:\/\/doi.org\/10.1016\/S1470-2045(16)30671-4","journal-title":"Lancet Oncol"},{"key":"4876_CR10","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M et al (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 132:2446\u20132455. https:\/\/doi.org\/10.1182\/blood-2018-05-850461","journal-title":"Blood"},{"key":"4876_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar MJ, Capra M, \u00d6zcan M et al (2021) Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 22:678\u2013689. https:\/\/doi.org\/10.1016\/S1470-2045(21)00145-5","journal-title":"Lancet Oncol"},{"key":"4876_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997\u20131007. https:\/\/doi.org\/10.1056\/NEJMoa1315226","journal-title":"N Engl J Med"},{"key":"4876_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/CCO.0000000000000113","volume":"26","author":"E Curran","year":"2014","unstructured":"Curran E, Smith SM (2014) Phosphoinositide 3-kinase inhibitors in lymphoma. Curr Opin Oncol 26:469\u2013475. https:\/\/doi.org\/10.1097\/CCO.0000000000000113","journal-title":"Curr Opin Oncol"},{"key":"4876_CR14","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1182\/blood.v98.10.3050","volume":"98","author":"A Bernal","year":"2001","unstructured":"Bernal A, Pastore RD, Asgary Z et al (2001) Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98:3050\u20133057. https:\/\/doi.org\/10.1182\/blood.v98.10.3050","journal-title":"Blood"},{"key":"4876_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88\u201392. https:\/\/doi.org\/10.1038\/nature08638","journal-title":"Nature"},{"key":"4876_CR16","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1080\/10428190412331272703","volume":"45","author":"I Munk Pedersen","year":"2004","unstructured":"Munk Pedersen I, Reed J (2004) Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 45:2365\u20132372. https:\/\/doi.org\/10.1080\/10428190412331272703","journal-title":"Leuk Lymphoma"},{"key":"4876_CR17","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3324\/haematol.2013.088849","volume":"98","author":"L Rosich","year":"2013","unstructured":"Rosich L, Saborit-Villarroya I, Lopez-Guerra M et al (2013) The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt\/FoxO3a\/Bim axis in chronic lymphocytic leukemia cells. Haematologica 98:1739\u20131747. https:\/\/doi.org\/10.3324\/haematol.2013.088849","journal-title":"Haematologica"},{"key":"4876_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","volume":"490","author":"R Schmitz","year":"2012","unstructured":"Schmitz R, Young RM, Ceribelli M et al (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490:116\u2013120. https:\/\/doi.org\/10.1038\/nature11378","journal-title":"Nature"},{"key":"4876_CR19","doi-asserted-by":"publisher","unstructured":"Okkenhaug K (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science.https:\/\/doi.org\/10.1126\/science.1073560","DOI":"10.1126\/science.1073560"},{"key":"4876_CR20","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.4049\/jimmunol.0900432","volume":"183","author":"CA Durand","year":"2009","unstructured":"Durand CA, Hartvigsen K, Fogelstrand L et al (2009) Phosphoinositide 3-kinase p110\u03b4 regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 183:5673\u20135684. https:\/\/doi.org\/10.4049\/jimmunol.0900432","journal-title":"J Immunol"},{"key":"4876_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S et al (2014) PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008\u20131018. https:\/\/doi.org\/10.1056\/NEJMoa1314583","journal-title":"N Engl J Med"},{"key":"4876_CR22","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM et al (2019) DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. JCO 37:912\u2013922. https:\/\/doi.org\/10.1200\/JCO.18.00915","journal-title":"JCO"},{"key":"4876_CR23","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L et al (2017) Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. JCO 35:3898\u20133905. https:\/\/doi.org\/10.1200\/JCO.2017.75.4648","journal-title":"JCO"},{"key":"4876_CR24","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Coutre SE, Furman RR et al (2019) Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol 37:1391\u20131402. https:\/\/doi.org\/10.1200\/JCO.18.01460","journal-title":"J Clin Oncol"},{"key":"4876_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","volume":"131","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, O\u2019Brien S, Kahl B et al (2018) Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4, \u03b3, is clinically active in advanced hematologic malignancies. Blood 131:877\u2013887. https:\/\/doi.org\/10.1182\/blood-2017-05-786566","journal-title":"Blood"},{"key":"4876_CR26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41375-020-01010-6","volume":"35","author":"MS Davids","year":"2021","unstructured":"Davids MS, Fisher DC, Tyekucheva S et al (2021) A phase 1b\/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia 35:1064\u20131072. https:\/\/doi.org\/10.1038\/s41375-020-01010-6","journal-title":"Leukemia"},{"key":"4876_CR27","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-19-3061","volume":"26","author":"MS Davids","year":"2020","unstructured":"Davids MS, Kuss BJ, Hillmen P et al (2020) Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed\/refractory CLL or SLL in the DUO crossover extension study. Clin Cancer Res 26:2096\u20132103. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3061","journal-title":"Clin Cancer Res"},{"key":"4876_CR28","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutr\u00e9","year":"2015","unstructured":"Coutr\u00e9 SE, Barrientos JC, Brown JR et al (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 56:2779\u20132786. https:\/\/doi.org\/10.3109\/10428194.2015.1022770","journal-title":"Leuk Lymphoma"},{"key":"4876_CR29","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","volume":"22","author":"AB Benson","year":"2004","unstructured":"Benson AB, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. JCO 22:2918\u20132926. https:\/\/doi.org\/10.1200\/JCO.2004.04.132","journal-title":"JCO"},{"key":"4876_CR30","first-page":"821","volume":"31","author":"IB Greenwell","year":"2017","unstructured":"Greenwell IB, Ip A, Cohen JB (2017) PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park) 31:821\u2013828","journal-title":"Oncology (Williston Park)"},{"key":"4876_CR31","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K et al (2017) Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 28:2169\u20132178. https:\/\/doi.org\/10.1093\/annonc\/mdx289","journal-title":"Ann Oncol"},{"key":"4876_CR32","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jamaoncol.2019.0034","volume":"5","author":"A Esposito","year":"2019","unstructured":"Esposito A, Viale G, Curigliano G (2019) Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: a review. JAMA Oncol 5:1347\u20131354. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0034","journal-title":"JAMA Oncol"},{"key":"4876_CR33","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","volume":"30","author":"NL Busaidy","year":"2012","unstructured":"Busaidy NL, Farooki A, Dowlati A et al (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30:2919\u20132928. https:\/\/doi.org\/10.1200\/JCO.2011.39.7356","journal-title":"J Clin Oncol"},{"key":"4876_CR34","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","volume":"21","author":"BW Miller","year":"2015","unstructured":"Miller BW, Przepiorka D, de Claro RA et al (2015) FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res 21:1525\u20131529. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2522","journal-title":"Clin Cancer Res"},{"key":"4876_CR35","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14656566.2020.1737010","volume":"21","author":"DL Kienle","year":"2020","unstructured":"Kienle DL, Stilgenbauer S (2020) Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Opin Pharmacother 21:917\u2013929. https:\/\/doi.org\/10.1080\/14656566.2020.1737010","journal-title":"Expert Opin Pharmacother"},{"key":"4876_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.hoc.2020.02.008","volume":"34","author":"RC Lynch","year":"2020","unstructured":"Lynch RC, Gopal AK (2020) Phosphatidylinositol-3-kinase inhibition in follicular lymphoma. Hematol Oncol Clin North Am 34:727\u2013741. https:\/\/doi.org\/10.1016\/j.hoc.2020.02.008","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04876-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T13:09:36Z","timestamp":1657717776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04876-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4876"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04876-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2022,6,11]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}